alan p. venook, md, provides his perspective on using tas-102 and regorafenib in crc patients
Published 7 years ago • 14 plays • Length 1:21
Download video MP4
Download video MP3
Similar videos
-
2:05
howard s. hochster, md, provides perspective on how to use tas-102 and regorafenib in crc patients
-
1:16
dr. eng on roles of regorafenib and tas-102 in crc treatment
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:44
alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms
-
26:20
colorectal cancer: the link between the immune microenvironment and outcomes
-
20:43
hereditary colorectal cancer
-
21:04
the immune and stromal classification of colorectal cancer
-
1:23
alan p. venook, md, on if the resorce trial will change the role of regorafenib
-
1:13
alan venook, md, on the impact of dose escalation of regorafenib in mcrc patients
-
2:06
howard s. hochster, md, differentiates regorafenib from 5fu and tas-102
-
4:53
debate: salvage therapy for mcrc? - tas-102 followed by regorafenib
-
0:25
alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc
-
2:47
mcrc: sequencing with regorafenib or tas-102
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients
-
7:54
regorafenib vs tas-102 salvage therapy
-
1:47
alan venook, md relays the optimal dose for regorafenib (stivarga) in the 2nd line treatment of mcrc
-
2:13
dr. lenz on the benefit of regorafenib in crc
-
4:54
the first oral fluoropyrimidine for mcrc—tas-102
-
2:03
alan venook, md, explains the biological difference between left-sided and right-sided crc tumors
-
0:50
dr. wu on possible combinations with tas-102 in crc
-
1:47
alan venook, md discusses development of immunotherapies for non msi-high crc patients
Clip.africa.com - Privacy-policy